Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Welcome to the latest edition of touchREVIEWS in Infectious Diseases, where we continue our mission to deliver insightful, cutting-edge perspectives in infectious disease diagnosis and management. This issue offers an array of topics spanning diagnostics, service delivery innovations and preventive care, reflecting the dynamic challenges and opportunities in our field. In our first editorial, Barbara […]

Mahmoud Ghannoum, IDWeek 2021: Unmet needs in the Treatment Vulvovaginal Candidiasis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 15th 2021

It was a pleasure to meet with Prof. Mahmoud Ghannoum (Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH, USA) to discuss the unmet needs in the treatment vulvovaginal candidiasis.

The abstract entitled: ‘Susceptibility Testing of Oteseconazole (VT-1161) Against Clinical Isolates from Phase 3 Clinical Studies in Subjects with Recurrent Vulvovaginal Candidiasis’ was presented at IDWeek 2021 (Virtual), 28 September – 3 October 2021.

Questions:

  1. Could you give us an overview of the health burden of vulvovaginal candidiasis (VVC)? (0:05)
  2. What are the unmet needs in the treatment of VVC? (1:37)

Disclosures: Mahmoud Ghannoum is contracted to conduct research from Mycovia pharmaceuticals, Scynexis, Amplyx Pharma, Gilead and Pfizer.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of IDWeek, Virtual 2021

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup